DexCom (DXCM) Securities Class Action Lawsuit

Shamis & Gentile, P.A. reminds investors of the upcoming lead plaintiff deadline of December 26, 2025, in the class action filed on behalf of investors who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (DXCM) securities between July 26, 2024 and September 17, 2025 (the “Class Period”).

Investors who purchased DexCom securities during the Class Period may be eligible to serve as lead plaintiff. Contact the firm now for more information on how to participate. The deadline to apply for lead plaintiff is December 26, 2025.

The class action complaint alleges that DexCom and certain executives made materially false and misleading statements and failed to disclose material information about the Company’s G6 and G7 continuous glucose monitoring (CGM) systems. According to the complaint, DexCom made design modifications to its sensors without prior FDA authorization, which allegedly affected device accuracy and increased regulatory scrutiny. The complaint further alleges that on March 7, 2025, DexCom disclosed an FDA warning letter addressing quality-control processes.

Following the disclosure, DexCom’s stock fell from $77.84 on March 7 to $70.72 on March 10, 2025.

On March 25, 2025, after the FDA published the warning letter stating the Company had modified its sensors without clearance, DexCom’s stock declined again, from $75.32 on March 24 to $72.13 on March 26, 2025.

Later in the Class Period, market reports highlighted continued concerns about the G7 system. On September 8, 2025, market analysts downgraded DexCom, and the stock fell from $80.51 to $78.00.

Following a September 18, 2025 report citing FDA documents and discussing additional performance issues, DexCom’s stock dropped from $76.44 to $67.45 by September 19, 2025, resulting in significant losses for investors.

If you purchased or otherwise acquired DexCom (DXCM) securities between July 26, 2024 and September 17, 2025, you may have important legal rights. The deadline to seek appointment as lead plaintiff is December 26, 2025.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.